Atypical hemolytic uremic syndrome, known as aHUS, is a rare and serious blood disorder in which uncontrolled activation of the body’s own immune defense system damages the lining of small blood vessels, leading to blood clots in tiny vessels throughout the body, destruction of red blood cells, low platelet counts, and kidney failure.1PubMed Central. Atypical Hemolytic Uremic Syndrome: A Brief Review The disease is driven by the complement system, a network of proteins that normally helps fight infections but in aHUS turns on the body’s own tissues. What makes aHUS especially challenging is the interplay of genetic vulnerability, unpredictable triggers, and the potential for damage well beyond the kidneys.
What Happens in aHUS
The complement system is part of your innate immune defenses. One of its branches, the alternative pathway, is always running at a low level, constantly surveilling for foreign invaders. In healthy people, a set of regulatory proteins keeps this activity in check so it does not attack the body’s own cells. In aHUS, that regulation fails. The alternative pathway fires continuously and deposits damaging proteins on the inner lining of small blood vessels, especially in the kidneys.2Child Kidney Dis. Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies
This sustained attack injures the endothelium, the thin layer of cells that lines every blood vessel. Once the endothelium is damaged, platelets rush in and clump together, forming tiny clots that narrow or block the vessels. Red blood cells trying to squeeze through these obstructed vessels get shredded in the process, which is why lab tests show fragmented red cells and falling hemoglobin. The result is a condition called thrombotic microangiopathy, or TMA, defined by three features: destruction of red blood cells, low platelet counts, and organ damage, particularly acute kidney injury.3PubMed Central. Atypical hemolytic uremic syndrome
The kidneys are hit hardest in part because of the anatomy of their filtering units. Research has shown that glomerular endothelial cells, the tiny blood vessel cells inside the kidney’s filters, are uniquely vulnerable to complement overactivation. When exposed to hemolysis-derived heme (a byproduct of red blood cell destruction), these cells fail to mount an adequate protective response, binding less of the regulatory protein Factor H and failing to ramp up a key protective enzyme. This makes the kidney a hotspot for the vicious cycle of clotting, cell destruction, and more complement activation.4PubMed Central. Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1
The Genetic Roots
Most people with aHUS carry mutations in genes that code for complement regulatory proteins. The first mutations discovered were in complement Factor H, a protein that acts as a brake on the alternative pathway. When Factor H is altered, it loses the ability to protect the body’s own cells from complement attack.5PubMed Central. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome Since then, researchers have found mutations in several other regulatory genes, including Factor I, membrane cofactor protein (MCP), and thrombomodulin, all of which reduce the body’s ability to rein in complement. On the flip side, gain-of-function mutations in complement components C3 and Factor B have also been identified; these make the complement attack machinery more powerful or harder to shut down.6PubMed Central. Genetics and complement in atypical HUS
Factor B mutations, for instance, produce altered proteins that either form a more stable attack complex or resist being broken apart by the body’s complement regulators.7PubMed Central. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome What’s important to understand is that carrying a mutation doesn’t guarantee you’ll develop aHUS. Many people with these variants live their whole lives without an episode. The mutations create vulnerability, but it usually takes an external trigger to tip the balance.
Triggers That Set Off an Episode
A wide range of stressors can push a genetically susceptible person into a full-blown aHUS episode. Common triggers include infections (particularly upper respiratory and gastrointestinal infections), pregnancy and the postpartum period, certain medications, autoimmune conditions, malignant hypertension, organ transplantation, and cancer.8PubMed Central. Complement in Secondary Thrombotic Microangiopathy When these conditions activate the complement system even modestly, the absence of proper regulation in a vulnerable person lets the response spiral out of control.
This is why aHUS can appear to come out of nowhere. A person who has carried a complement mutation for decades might develop the disease after a routine viral illness, after giving birth, or after starting a new medication. The trigger itself may be unremarkable, but it is enough to overwhelm an already compromised regulatory system.
Telling aHUS Apart from Related Conditions
The trio of red blood cell destruction, low platelets, and organ damage is not unique to aHUS. Thrombotic thrombocytopenic purpura (TTP) and typical HUS caused by Shiga-toxin-producing bacteria (often from food poisoning with certain E. coli strains) can look almost identical on initial blood work. Getting the diagnosis right matters enormously because the treatments are completely different.
TTP is caused by a severe deficiency in an enzyme called ADAMTS13 that normally processes a blood-clotting protein. Unlike aHUS, where complement is the problem, TTP is treated with plasma exchange and immunosuppression aimed at ADAMTS13. The most informative test for separating them is measuring ADAMTS13 activity in the blood. A very low level points strongly toward TTP, while normal or near-normal activity in the setting of TMA raises suspicion for aHUS.9PubMed Central. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies In children, typical HUS following a diarrheal illness is relatively straightforward to identify, but in adults, separating aHUS from TTP and other microangiopathic disorders can be a real diagnostic challenge.10PubMed Central. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
One reason diagnosis takes time is that genetic testing for complement mutations can take weeks to return. Clinicians often have to start treatment before results are available, based on the clinical picture and the ADAMTS13 result. This is part of what makes aHUS such a high-stakes condition: delays in the correct treatment can mean permanent kidney damage.
Beyond the Kidneys
Although kidney failure dominates the clinical picture, aHUS is a systemic disease. The complement attack and microvascular clotting can affect blood vessels throughout the body. A systematic review of extrarenal involvement found that the central nervous system was the most commonly affected organ system outside the kidneys, occurring in roughly 28% of patients, with seizures as the leading symptom. Gastrointestinal symptoms followed at about 31% (in those studies reporting GI involvement), and cardiovascular problems appeared in around 16%.11PubMed Central. Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis
Extrarenal manifestations can show up during the acute flare, but some develop over time as long-term consequences of ongoing complement activation. The peripheral nervous system, lungs, skin, and eyes can all be involved.12PubMed Central. Extra-renal manifestations of atypical hemolytic uremic syndrome Recognizing these signs is important because they can be the first clue that something more than straightforward kidney disease is going on, especially in patients who have not yet received a diagnosis.
Children Versus Adults
aHUS behaves somewhat differently depending on the patient’s age. A nationwide French study comparing children and adults found that mortality was higher in children than in adults in the first year after diagnosis (roughly 7% versus under 1%). However, adults were far more likely to progress to end-stage kidney disease after their first episode, with about 46% of adults reaching that point compared to 16% of children. Outcomes associated with mutations in membrane cofactor protein (MCP) and cases without an identified genetic cause tended to be milder in children.13PubMed Central. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults
The reasons for these differences are not fully settled, but part of the explanation may lie in the distribution of specific mutations across age groups and differences in how quickly the disease is recognized and treated. In young children, the onset can be more explosive and harder to stabilize, while in adults, the disease may smolder longer before diagnosis, leading to more irreversible kidney scarring.
Treatment With Complement Inhibitors
The development of complement-blocking drugs fundamentally changed the outlook for people with aHUS. Before these drugs were available, the main option was plasma exchange, which supplies functional complement regulators and removes dysfunctional ones. Plasma exchange helped some patients but was far from a cure, and long-term kidney outcomes remained poor for many.
Eculizumab, a monoclonal antibody that blocks complement component C5, was the first targeted therapy. By preventing C5 from being cleaved, it stops the formation of the membrane attack complex, the final destructive product of complement activation. Its arrival was described as one of the major breakthroughs in aHUS management.14PubMed. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy
Ravulizumab is a newer C5 inhibitor engineered to last longer in the body, which means less frequent dosing: a loading dose followed by infusions every four to eight weeks rather than every two weeks. In phase 3 trials, ravulizumab resolved TMA in 54% of adult patients and 78% of pediatric patients within 26 weeks, using a strict outcome measure that required simultaneous improvement in both blood counts and kidney function. The drug was generally well tolerated, and children who had previously responded to eculizumab maintained stable blood and kidney parameters after switching.15PubMed Central. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
Can Treatment Be Stopped?
Because complement inhibitors are expensive, require lifelong infusions, and carry their own risks, the question of whether patients can safely stop treatment is a pressing one. A prospective multicenter study found that discontinuing eculizumab based on the patient’s complement genetic profile is reasonable and safe. The study showed that certain factors, including female sex and carrying a rare variant in a complement gene, were linked to a higher risk of relapse after stopping. But with careful monitoring and a genetics-informed approach, many patients were able to discontinue treatment, improving their quality of life and reducing costs.16Blood. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study
This is a nuanced decision. A patient with an MCP mutation, for example, may have a very different risk profile than someone with a Factor H mutation. Stopping treatment is not the right call for everyone, and patients who do stop require close follow-up so treatment can be restarted quickly if the disease recurs.
The Infection Trade-Off
Blocking complement C5 has a well-known trade-off: the terminal complement pathway is essential for fighting certain encapsulated bacteria, particularly Neisseria meningitidis, the cause of meningococcal meningitis. Patients on eculizumab or ravulizumab are at increased risk for meningococcal infections and must be vaccinated before starting treatment.17PubMed Central. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab In young infants who cannot yet receive meningococcal vaccines, prophylactic antibiotics are used as a stopgap. The infectious risk is manageable but not trivial, and it is one of the reasons clinicians weigh the decision to start or continue therapy carefully.
Pregnancy-Associated aHUS
Pregnancy is one of the most recognized triggers for aHUS. The disease typically presents in the postpartum period, often after a pregnancy complication, and can be devastating if not recognized quickly.18PubMed Central. Pregnancy-Associated Atypical Hemolytic Uremic Syndrome A Systematic Review In genetically predisposed women, the physiological complement activation that accompanies normal pregnancy and delivery can be enough to trigger the disease. The result is a rapid-onset hemolytic crisis with acute kidney injury that demands immediate intervention.19PubMed Central. Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome
Distinguishing pregnancy-associated aHUS from other conditions that cause similar symptoms in late pregnancy or postpartum, such as HELLP syndrome, severe preeclampsia, or TTP, is critical and often difficult. Complement testing, autoantibody panels, and genetic testing all play a role in arriving at the correct diagnosis.20PubMed Central. A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy Treatment with eculizumab has dramatically improved outcomes: a meta-analysis found that eculizumab treatment significantly reduced the risk of chronic kidney disease and end-stage kidney disease in pregnancy-associated aHUS, cutting that risk by about 80%.21PubMed Central. Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: A systematic review and meta-analysis
The Autoimmune Variant
Not all aHUS is caused by genetic mutations. A subset of patients, particularly children and adolescents, develop antibodies against Factor H that disable the protein just as effectively as a mutation would. This autoimmune form of aHUS has its own treatment approach: because the problem is an antibody rather than a permanent genetic change, plasma exchange to remove the antibodies and immunosuppressive therapy to prevent their production can be effective, sometimes in combination with eculizumab.22PubMed Central. Anti-factor H antibody and its role in atypical hemolytic uremic syndrome
Testing for anti-Factor H antibodies is an important step in the diagnostic workup because the treatment implications are significant. A patient with this autoimmune form might eventually be able to taper off complement inhibitors once the antibody response is suppressed, while a patient with a permanent genetic defect faces a different long-term treatment calculus.
Kidney Transplantation
For patients who progress to end-stage kidney disease, transplantation was historically viewed with extreme caution. The recurrence rate after transplantation was high, and graft loss was common. The specific genetic mutation matters enormously here: mutations in genes for circulating complement proteins (Factor H, Factor B, C3) carry a much higher recurrence risk than mutations in membrane-bound proteins like MCP, since MCP is expressed on the donor kidney and comes along with the transplant.
A large study found that carrying a mutation, especially in Factor H, was strongly associated with post-transplant recurrence. Hybrid gene mutations involving Factor H were particularly risky; all grafts in one series experienced recurrence in the first year. Preemptive plasma therapy before transplantation significantly reduced graft loss.23American Journal of Transplantation. Use of Complement Genetic Abnormalities to Predict aHUS Recurrence after Renal Transplantation Eculizumab has changed the landscape substantially: prophylactic and maintenance complement blockade now allows many high-risk patients to undergo successful transplantation, which was previously considered contraindicated for them.24PubMed Central. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature
Secondary Forms and Overlapping Conditions
The boundary between “primary” aHUS, caused by genetic complement defects, and “secondary” TMA, where complement activation happens in the setting of another disease, is blurrier than textbooks once suggested. Conditions like autoimmune diseases, malignant hypertension, certain cancers, and drug toxicity can trigger TMA that looks clinically identical to primary aHUS. In a large cohort of patients with secondary hemolytic uremic syndrome, rare complement gene variants were found in only about 5% of cases. But the absence of a genetic abnormality doesn’t rule out complement involvement in driving the disease.25PubMed. Secondary atypical hemolytic uremic syndromes in the era of complement blockade
This gray zone creates real clinical dilemmas. Should a patient with lupus who develops TMA receive a complement inhibitor, or should the focus be entirely on controlling the underlying autoimmune disease? The evidence is still evolving, and decisions often come down to how severe the TMA is, whether it responds to treating the underlying condition, and whether there are signs of specific complement activation. It’s one of the more active areas of research in the field.
Emerging Oral Therapies
Current complement inhibitors are given by intravenous infusion, which means regular hospital or clinic visits for the foreseeable future. This is a significant burden, especially for children and for patients in areas with limited access to infusion centers. The next generation of treatments aims to change that.
Iptacopan is an oral small-molecule drug that targets Factor B, blocking the alternative complement pathway upstream of where current C5 inhibitors act. A phase 3 clinical trial called APPELHUS is evaluating iptacopan in 50 patients with primary complement-mediated aHUS who have not previously received complement inhibitor therapy. Patients take 200 mg by mouth twice daily, and the primary goal is to see how many achieve complete TMA response within 26 weeks without needing plasma exchange or anti-C5 therapy.26ScienceDirect / Kidney International Reports. Clinical Research Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome If successful, an oral option would represent a meaningful shift in how the disease is managed day-to-day, reducing the treatment burden that many patients cite as one of the most difficult aspects of living with aHUS.
Targeting Factor B rather than C5 also means intervening earlier in the complement cascade. In theory, this could prevent some of the upstream inflammatory damage that C5 inhibitors do not fully address, though whether that translates into better clinical outcomes remains to be seen.